Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Prevymis (letermovir) is an antiviral medicine approved by the FDA for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients (6 months and older, weighing at least 6 kg) who are CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant, and for CMV disease prophylaxis in adult and pediatric kidney transplant recipients (12 years and older, weighing at least 40 kg) at high risk.
Prevymis inhibits the CMV DNA terminase complex, which is required for viral DNA processing and packaging during CMV replication. By blocking this step, Prevymis helps prevent CMV from establishing infection after transplantation, a period when patients are particularly vulnerable due to immunosuppression.
Prevymis is intended for transplant recipients at risk of CMV reactivation or infection, used as prophylaxis rather than treatment of active CMV disease.
For HSCT recipients, the recommended dose is 480 mg once daily (orally or intravenously), starting after transplantation through Day 100, or 240 mg once daily if co-administered with cyclosporine.
Prevymis does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Prevymis has significant interactions with CYP3A substrates, immunosuppressants such as cyclosporine and tacrolimus, and certain statins, requiring dose adjustment or close monitoring during coadministration.
The intravenous formulation contains hydroxypropyl betadex, which can accumulate in patients with renal impairment and carries a potential risk of ototoxicity; the oral formulation is preferred where feasible in these patients.
Prevymis is intended for prophylaxis, not treatment of active CMV infection or disease. A treating physician should confirm the appropriate use based on the patient's clinical status.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Prevymis is manufactured and marketed by Merck Sharp & Dohme. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating transplant physician confirming transplant status and CMV serostatus. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for CMV prophylaxis in transplant recipients, Prevymis is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Prevymis directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Prevymis should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, in its original carton to protect from light, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Prevymis through NPP's regulated import pathway, with transplant specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support transplant care coordination and documentation for Prevymis access.
Delhi's major hospitals assist patients with prescription support and documentation for Prevymis.
Bangalore's specialist network offers access coordination for eligible transplant patients seeking Prevymis.
Chennai-based transplant specialists coordinate Prevymis access alongside comprehensive post-transplant care.
Hyderabad's care institutions support patients pursuing Prevymis therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Prevymis.
Pune-based specialists assist with prescription support and Prevymis treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Prevymis.
Kochi's specialist units assist patients with the documentation needed for Prevymis access.
Chandigarh's care centers support Prevymis treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Prevymis access process.
Lucknow-based centers assist patients pursuing Prevymis therapy.
Bhubaneswar's institutions support access to Prevymis for eligible patients.
Guwahati's specialists help coordinate Prevymis access for patients across the Northeast.
Patients in other cities across India can also access Prevymis through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
